Objective:

To explore the efficacy of infliximab (IFX) in treating non-Crohn’s disease-related fistulas in a patient with a complex medical history, including prostate cancer and recurrent infections.

Approach:

Key Findings:

• Significant clinical improvement was reported within 2 weeks of starting IFX, with the patient experiencing no abdominal pain and gaining 6 kg after 22 weeks.
• At 1-year follow-up, no further hospitalizations for uncontrolled infection were reported, and MRI showed a reduction in the size of the presacral wound cavity.

Interpretation:

This case suggests that infliximab may be an effective treatment option for non-CD-related fistulas when other therapies fail, aligning with limited existing literature on the subject.

Limitations:

• The study is based on a single case report, limiting generalizability to broader populations.
• Histological examination did not confirm Crohn's disease, raising questions about the underlying pathology and the applicability of findings to similar cases.

Conclusion:

Infliximab may represent a viable therapeutic option for patients with refractory non-CD-related fistulas, warranting further investigation in larger studies.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.